Table 1

Baseline characteristics for 11 neonates treated with amphotericin B lipid complex (ABLC)

Patient no Age (weeks) Weight (kg) Pre-existing conditions Site of positive culture Candida spp. Reason for ABLC use
150.7Prematurity (24 weeks), cardiac and aortic thrombi, NECBlood, skin/soft tissue, lung1-150 C albicans Nephrotoxicity, failure of prior antifungal
285.0Intestinal obstruction s/p laparotomy, Hirschsprung's diseaseBlood, lung1-150 C parapsilosis Failure of prior antifungal
3141.4Prematurity, NECBlood C tropicalis Failure of prior antifungal
473.5Transposition of the great vessels s/p repair, renal failure post-op, peritoneal dialysisBlood, urine, peritoneal fluid C albicans Nephrotoxicity, failure of prior antifungal
531.1Prematurity (26 weeks), NEC, bowel perforationBlood, urine, peritoneal fluid C albicans Nephrotoxicity, failure of prior antifungal
630.8Prematurity (26 weeks), repair of PDA, NEC, bowel perforationBlood, urine, peritoneal fluid C albicans Nephrotoxicity
743.7Repair of PDA, chest tubeBlood C tropicalis Failure of prior antifungal
832.3Prematurity, congenital renal dysplasia 2° posterior urethral valvesSkin/soft tissue, urine C albicans Underlying renal disease
981.1Prematurity (26 weeks), NEC, prior candidaemiaBlood C parapsilosis Failure of prior antifungal
1070.9Prematurity (23 weeks), NEC, decubitiBlood, skin/soft tissue C parapsilosis Failure of prior antifungal
1182.5Prematurity (32 weeks), Langerhans cell histiocytosis, renal failure, neutropeniaBlood C albicans,C glabrata Underlying renal disease, failure of prior antifungal

  • ↵1-150 For patients 1 and 2, yeast grew from endotracheal tube aspirates and chest radiographs showed pneumonia. The treating clinician made the diagnosis of Candidapneumonia.

  • NEC, necrotising enterocolitis; PDA, patent ductus arteriosus.